Trevi Therapeutics Overview
Valuation check: TRVI's ROE is -26.5%, below the Healthcare sector average of 29.39%.
Get informed when a big investor buys or sells
+ Follow-26.50%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Trevi Therapeutics (TRVI) currently reports a ROE of -26.5%. That is below the Healthcare sector average of 29.39%. Use the charts on this page to explore Trevi Therapeutics's ROE history and peer comparisons.
Trevi Therapeutics's ROE of -26.5% is lower than the Healthcare sector average of 29.39%. That is roughly 190.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Trevi Therapeutics's current -26.5% should be judged against Healthcare norms (sector average: 29.39%) and against TRVI's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -26.5%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.39%. From there, open related valuation or income-statement pages for Trevi Therapeutics, and consider following TRVI for alerts when major investors trade the stock.
Trevi Therapeutics is classified in the Healthcare sector. On ROE, it currently shows -26.5% versus a sector average near 29.39%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TRVI with unrelated industries.
